AquaBounty ‘on track’ to sell GM salmon by year’s end, despite court ruling calling for more environmental impact data

The FDA should have given more consideration to the risks genetically modified AquAdvantage salmon posed to wild populations before approving the new breed of fish, a federal judge ruled last week. U.S. District Judge Vince Chhabria ordered the agency to reconsider the environmental assessment for the salmon, but did not withdraw FDA approval.

AquaBounty, the company that created and produces AquAdvantage, is still on track to start selling the genetically modified fish at the end of this year. “While we were disappointed with some of the conclusions reached in the judge’s decision regarding the environmental assessment conducted by the U.S. Food and Drug Administration (FDA), we remain confident in the robust scientific studies and review that resulted in the 2015 FDA approval,” AquaBounty President and CEO Sylvia Wulf said in an emailed statement.

…

What this court ruling does accomplish is raising the bar for future GM meat approval from FDA. The approval for AquAdvantage salmon was given after long and careful study about the chances of the GM fish escaping into the wild and interfering with existing salmon populations.

Related on the SLP

AquaBounty acquires first US fish farm to raise fast-growing GE salmon Health Canada approves AquaBounty GMO salmon for commercial sale

Abortion rights opponents outraged after FDA says its “safety review” of the already-found-safe mifepristone abortion pill will continue into 2027

GAHA: The corporate-created “healthier America” movement challenging what it claims is MAHA misinformation about modern farming, chemicals, and food

9 wellness myths busted

…

But, the judge wrote, a proper and detailed assessment of the risks posed by AquAdvantage to the wild — which was not done because of the remote possibility it would occur — needs to be in the official record.

Read the original post